Impact of intermittent fasting on patients with cancer undergoing chemotherapy and/or targeted therapies: a systematic review of the literature
Maes J, Durieux V, Liebmann M, Salmon M, Preiser JC
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 4 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2025-09-19 · Support Care Cancer · vol. 33 · número 10 · pág. 863
- Editorial
- Springer Science+Business Media
- Citado
- 3 citas · más que el 60% de estudios similares · 0.6× el promedio de su campo
- Referencias
- 22 trabajos
- Acceso
- De pago
- Áreas de investigación
- Dietary Effects on Health · Enhanced Recovery After Surgery · Diet and metabolism studies
- Palabras clave
- intermittent fasting, cancer patients, chemotherapy, targeted therapy, breast cancer, chemotherapy toxicity, insulin, insulin-like growth factor I, red blood cell count, body weight, adjunctive therapy
- MeSH
- humans, neoplasms, antineoplastic agents, fasting, quality of life, molecular targeted therapy, intermittent fasting
5 autores
- Juliette Maes🇧🇪 · autor de correspondenciaInstitut Jules Bordet
- Valérie Durieux🇧🇪Université Libre de Bruxelles
- Margaux Liebmann🇧🇪Université Libre de Bruxelles
- Maurine Salmon🇧🇪Institut Jules Bordet
- Jean‐Charles Preiser🇧🇪Institut Jules Bordet
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose
Intermittent fasting holds potential for improving cancer patient outcomes by promoting cancer cell death. Additionally, it depletes hepatic glycogen reserves, facilitating the release of fatty acids and ketones, which may enhance cancer cells sensitivity to chemotherapy and impede their proliferation. However, clinical data on fasting among cancer patients remain scarce. This systematic review intends to provide an overview of the impact of intermittent fasting on the safety, feasibility, tolerability, and metabolic effects of chemotherapy and targeted therapies in cancer patients.
Methods
Articles were retrieved from 1990 to March 2025, employing a defined search equation. Established endpoints included cancer development, treatment efficacy, side effects related to chemotherapy and targeted therapies, quality of life, and fasting tolerance. Risk of bias was assessed, utilizing a validated assessment tool.
Results
Among 1,725 articles, nine met our inclusion criteria. Risk of bias was low to moderate. These studies included patients predominantly with breast cancer (n = 258/354). Even though the safety and feasibility of intermittent fasting were confirmed, no impact on treatment outcomes and chemotherapy-related toxicities was demonstrated. However, a consistent trend emerged in reduced insulin and IGF-1 levels, along with increased erythrocyte levels among fasting patients. Three studies reported no significant difference in body weight and BMI.
Conclusion
Current evidence indicates that intermittent fasting is both safe and feasible. However, due to the lack of robust evidence, a definitive conclusion regarding the impact of intermittent fasting on treatment effectiveness and side effects related to chemotherapy and targeted therapies in cancer patients cannot be drawn. Larger randomized controlled trials are warranted to validate intermittent fasting as an adjunctive therapeutic approach.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.